Article Versions Notes

Di Giorgio C, Lupia A, Marchianò S, Bordoni M, Bellini R, Massa C, Urbani G, Roselli R, Moraca F, Sepe V, et al. Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma. Cells. 2022; 11(21):3482. https://doi.org/10.3390/cells11213482

Di Giorgio, Cristina, Antonio Lupia, Silvia Marchianò, Martina Bordoni, Rachele Bellini, Carmen Massa, Ginevra Urbani, Rosalinda Roselli, Federica Moraca, Valentina Sepe, and et al. 2022. "Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma" Cells 11, no. 21: 3482. https://doi.org/10.3390/cells11213482

Di Giorgio, C., Lupia, A., Marchianò, S., Bordoni, M., Bellini, R., Massa, C., Urbani, G., Roselli, R., Moraca, F., Sepe, V., Catalanotti, B., Morretta, E., Monti, M. C., Biagioli, M., Distrutti, E., Zampella, A., & Fiorucci, S. (2022). Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma. Cells, 11(21), 3482. https://doi.org/10.3390/cells11213482